DISEASE CHARACTERISTICS: - Histologically confirmed prostate cancer - Metastatic disease - Has ≥ 1 convincing bone metastasis by bone scintigraphy, CT scan/MRI, or plain x-ray - Castration-resistant disease - Castrate testosterone levels (< 50 ng/dL) - Has undergone prior orchiectomy OR is currently on maintenance luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist - Scheduled to receive treatment with dasatinib on the Febbo clinical trial PATIENT CHARACTERISTICS: - Life expectancy > 12 weeks - Able to lie still for imaging - Weighs ≤ 300 lbs. - No condition that would alter mental status and preclude the basic understanding and/or authorization of informed consent - No serious underlying condition that would otherwise impair the patient's ability to receive treatment and undergo imaging studies - No extremely poor IV access that would preclude the placement of a peripheral IV line for injection of a radiotracer PRIOR CONCURRENT THERAPY: - See Disease Characteristics - At least 4 weeks since prior initiation of bisphosphonate therapy - At least 4 weeks since prior radiotherapy to the bone - At least 4 weeks since prior radiopharmaceutical treatment to the bone - More than 4 weeks since prior GM-CSF or G-CSF